Autres langues Voyageur Pharmaceuticals Ltd.

Actions

VM

CA92918C1014

Produits pharmaceutiques

Temps Différé Toronto S.E. 15:31:16 30/09/2026			Varia. 5j.	Varia. 1 janv.
0,1400 ^CAD	0,00 %		-6,67 %	-17,65 %

25/09	Voyageur Pharmaceuticals émettra des actions pour régler une dette de 192 300 dollars canadiens	MT
10/08	Voyageur Pharmaceuticals Ltd. progresse dans le processus d'extraction d'iode Mueller avec une pureté de 99,8 % et prévoit des tests pilotes sur le terrain	CI

Autres langues

25/09	Voyageur Pharmaceuticals to Issue Shares to Settle Debt of CA$192,300
24/09	Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt
10/09	(PODCAST) Voyageur Pharmaceuticals (TSXV:VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment
09/09	Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment
10/08	Voyageur Pharmaceuticals Ltd. Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing
10/08	Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing
24/07	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2026
17/07	Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
23/06	Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
18/06	Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility
18/06	Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
10/06	Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project
10/06	Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
06/06	Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
05/06	Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding
01/05	Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding
01/05	Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026
24/04	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026
17/04	Voyageur Announces Shares for Debt Settlement and Stock Option Repricing
27/03	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025
27/03	Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt
24/03	Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding
16/03	Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
05/03	Voyageur Pharmaceuticals : Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant
04/03	Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient